Introduction
============

Colorectal cancer (CRC) is one of the most common digestive malignancies, and it arises through well-defined sequential multi-step carcinogenesis that transforms normal glandular epithelium into invasive adenocarcinomas ([@b1-ol-0-0-8393],[@b2-ol-0-0-8393]). The development of CRC involves genetic and epigenetic modifications. Aberrant DNA methylation within gene promoters is a primary mediator of epigenetic inheritance in CRC ([@b3-ol-0-0-8393],[@b4-ol-0-0-8393]).

DNA methylation typically occurs in CpG islands and it refers to the enzymatic addition of a methyl group to the 5′ position of cytosine by DNA methyltransferases to produce 5-methyl cytosine. Methylation of CpG islands in the gene promoter region may induce chromatin conformational modifications that inhibit access of transcriptional machinery, altering gene expression levels ([@b5-ol-0-0-8393],[@b6-ol-0-0-8393]). Therefore, promoter methylation is commonly associated with gene silencing and promoter demethylation with gene expression ([@b7-ol-0-0-8393],[@b8-ol-0-0-8393]).

There are complex changes of DNA methylation in a number of carcinomas, and particularly in CRC ([@b9-ol-0-0-8393],[@b10-ol-0-0-8393]). Numerous genes are aberrantly methylated in CRC patients, including adenomatous polyposis coli (*APC*), *WNT5A*, mutL homolog 1 (*MLH1*), cyclin-dependent kinase inhibitor 2A (*CDKN2A*) and Ras association domain-containing protein 1 ([@b11-ol-0-0-8393]--[@b15-ol-0-0-8393]). Aberrant DNA methylation of gene promoters in CRC is involved in its occurrence, progression, diagnosis, staging, prognosis and response to chemotherapy ([@b16-ol-0-0-8393]).

The protocadherin gamma subfamily A12 (*PCDH*-γ-*A12*) gene encodes a cell surface adhesion protein that serves essential roles in cell-cell and cell-matrix interactions and tumor metastasis ([@b17-ol-0-0-8393],[@b18-ol-0-0-8393]). The solute carrier family 19 A 1 (*SLC19A1*) gene encodes a membrane protein that is involved in the regulation of intracellular concentrations of folate ([@b19-ol-0-0-8393]). *SLC19A1* gene mutation is associated with the risk of CRC ([@b20-ol-0-0-8393]). The cAMP responsive element binding protein (*CREB*) gene encodes a transcription factor that induces the transcription of genes in response to hormonal stimulation of the cAMP pathway ([@b21-ol-0-0-8393],[@b22-ol-0-0-8393]). P300/CREB binding protein genes promote cancer progression in colon cancer cell lines with microsatellite instability ([@b23-ol-0-0-8393]). Cylindromatosis (*CYLD*) encodes a cytoplasmic protein with three cytoskeletal-associated protein-glycine-conserved domains, and it regulates cell proliferation, apoptosis, cell movement and cell differentiation ([@b24-ol-0-0-8393]--[@b27-ol-0-0-8393]). CYLD is downregulated or lost in colon carcinoma cell lines compared with primary human colonic epithelial cells. The functional relevant loss of CYLD expression may contribute to tumor development and progression, and it may provide a new target for therapeutic strategies ([@b28-ol-0-0-8393]).

Promoter methylation of the *PCDH*-γ-A12, *SLC19A1*, *CREB* and *CYLD* genes has been demonstrated to regulate their gene expression levels, and hypermethylation of these promoters has been observed in acute lymphoblastic leukemia ([@b29-ol-0-0-8393]), breast cancer ([@b30-ol-0-0-8393],[@b31-ol-0-0-8393]) and malignant melanoma ([@b32-ol-0-0-8393]). However, hypermethylation of the *PCDH*-γ-A12, *SLC19A1*, *CREB* and *CYLD* promoters has not been investigated in CRC. In light of the previous findings, the aim of the present study was to investigate whether *PCDH*-γ-A12, *SLC19A1*, *CREB* and *CYLD* gene promoter methylation contributed to the risk of CRC.

Materials and methods
=====================

### Tissue sample collection

In this study, CRC patients who had not received radiotherapy, chemotherapy, targeted therapy or dendritic cell/cytokine-induced killer therapy prior to surgery were recruited between June 2012 and April 2013 ([Table I](#tI-ol-0-0-8393){ref-type="table"}). CRC samples, normal adjacent tissue samples and matched metastatic lymph node samples were collected at the time of surgery from 42 primary sporadic CRC patients at the Department of Gastrointestinal Surgery in the Affiliated Hospital of Ningbo University, China. Tissues were immediately preserved in liquid nitrogen at −80°C following removal from the body and stored at −80°C until use. Normal adjacent tissues were collected from at least 5 cm away from the edge of the tumor, and there were no obvious tumor cells, as evaluated by a pathologist. Tumor stage was determined according to Dukes\' staging system, and cellular differentiation was graded according to Broders\' grading system. Informed consent was given by all subjects. The Human Research Ethics Committee of Ningbo University approved all aspects of the study.

### DNA isolation and bisulfite modification

Genomic DNA was isolated using a QIAamp DNA mini kit (Qiagen GmbH, Hilden, Germany). The concentration and quality of genomic DNA were determined using the NanoDrop ND-2000 spectrophotometer (Thermo Fisher Scientific, Inc., Waltham, MA, USA). The concentration of DNA was above 30 ng/µl and the purity of DNA was at the A260/A280 ratio of 1.7--1.9. DNA was bisulfite-treated with the EZ DNA Methylation-Gold kit (Zymo Research, Orange, CA, USA). Following the completion of bisulfite modification, all unmethylated cytosines in CpG islands were converted to uracil, while methylated cytosines remained unchanged.

### Methylation-specific polymerase chain reaction (MSP) and bisulfite sequencing

The methylated and unmethylated primers ([Table II](#tII-ol-0-0-8393){ref-type="table"}) were designed using the Primer Premier 6.0 program (Premier Biosoft International, Palo Alto, CA, USA). MSP was performed in a total volume of 20 µl containing 2 µl bisulfite modified DNA, 1 µmol each of forward and reverse primers, 10 µl Premix Taq (Takara Biotechnology Co., Ltd., Dalian, China) and 7 µl double-distilled water with the following cycling parameters: 10 min of denaturation at 95°C followed by 55 cycles of 30 sec at 95°C, 45 sec at 72°C and a final extension for 10 min at 72°C. Polymerase chain reaction (PCR) products were then loaded and electrophoresed on 2% agarose gels, stained with ethidium bromide, and visualized under UV illumination. In order to confirm the result of methylation- and unmethylation-specific PCR, PCR products randomly obtained from the group were sequenced bidirectionally by Invitrogen (Thermo Fisher Scientific, Inc.) with the same primers used for MSP.

### Statistics

Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS) statistical software package (version 16.0; SPSS, Inc., Chicago, IL, USA), and the results were obtained using GraphPad Prism version 5.0 (GraphPad Software, Inc., La Jolla, CA, USA). All analyses were two-sided, and P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Methylation rates of promoters in CRC vs

### normal tissues

A total of 42 pairs of CRC and adjacent normal tissues were examined, and representative results of the agarose gel electrophoresis were selected ([Fig. 1](#f1-ol-0-0-8393){ref-type="fig"}). The results revealed that the methylation rates of *PCDH*-γ-*A12, SLC19A1, CREB* and *CYLD* promoters in CRC were 83.33% (35/42), 78.57% (33/42), 26.19% (11/42) and 14.29% (6/42), while the methylation rates of these promoters in normal tissues were 57.14% (24/42), 45.24% (19/42), 11.90% (5/42) and 11.90% (5/42). *PCDH*-γ-*A12* and *SLC19A1* gene promoters were more frequently methylated in CRC tissues than in normal tissues (83.33% vs. 57.14%, P=0.009 and 78.57% vs. 42.54%, P=0.002), while there was no significant difference in methylation rates of *CREB* and *CYLD* gene promoters between CRC tissues and normal tissues (26.19% vs. 11.90%, P=0.095 and 14.29% vs. 11.90%, P=0.746; [Table III](#tIII-ol-0-0-8393){ref-type="table"}).

### Methylation rates of promoters in lymph vs. non-lymph metastasis CRC tissues

In addition, the methylation rates of *PCDH*-γ-*A12, SLC19A1, CREB* and *CYLD* promoters in lymph metastasis CRC tissues were 100.00% (21/21), 95.24% (20/21), 33.33% (7/21) and 19.05% (4/21), while the methylation rates of these promoters in non-lymph metastasis CRC tissues were 66.67% (14/21), 61.90% (13/21), 19.05% (4/21) and 9.52% (2/21). *PCDH*-γ-*A12* and *SLC19A1* gene promoters were more frequently methylated in lymph metastasis CRC tissues than non-lymph metastasis CRC tissues (100.00% vs. 66.67%, P=0.013% and 95.24% vs. 61.90%, P=0.024), while there was no significant difference in the methylation rate of *CREB* and *CYLD* gene promoters between lymph metastasis CRC tissues and non-lymph metastasis CRC tissues (33.33% vs. 19.05%, P=0.292 and 19.05% vs. 9.52%, P=0.659; [Table IV](#tIV-ol-0-0-8393){ref-type="table"}).

### Bisulphite sequencing of PCDH-γ-A12, SLC19A1, CREB and CYLD genes

In order to confirm the results of the PCR-based methylation analysis describe above, high-resolution bisulfite genomic sequencing was performed in the stochastic samples derived from the methylation PCR experiments. In agreement with the MSP results, CpG dinucleotides of the *PCDH*-γ-*A12* and *SLC19A1* promoters in the samples demonstrated extensive hypermethylation, whereas the *CREB* and *CYLD* promoters were unmethylated at these CpG dinucleotides ([Fig. 2](#f2-ol-0-0-8393){ref-type="fig"}).

### Correlation between methylation status of promoters and clinicopathological factors

The correlation between the methylation status of the *PCDH*-γ-*A12, SLC19A1, CREB* and *CYLD* gene promoters and the clinicopathological characteristics of CRC is shown in [Table V](#tV-ol-0-0-8393){ref-type="table"}. There was no significant difference in clinicopathological factors, including sex, age, tumor-node-metastasis stage, lymph node status, metastasis status, tumor location, differentiation status, tumor size and histological grade. There was also no correlation between the methylation status of the *PCDH*-γ-*A12, SLC19A1, CREB* and *CYLD* gene promoters and the serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9).

Discussion
==========

Cancer develops through a multi-step process which results from the progressive accumulation of genetic and epigenetic alterations ([@b33-ol-0-0-8393]). Epigenetic modifications, which have a fundamental role in the regulation of gene expression, involve DNA methylation, specific histone modifications and non-coding RNA interventions ([@b34-ol-0-0-8393],[@b35-ol-0-0-8393]). As one of the main epigenetic modifications, DNA methylation of promoters often downregulates gene transcription, while DNA demethylation of promoters activates gene expression. DNA methylation-mediated tumor suppressor gene silencing may contribute to tumor progression ([@b7-ol-0-0-8393],[@b36-ol-0-0-8393]). Aberrant DNA methylation of gene promoters has become a promising biomarker for the early diagnosis of diseases ([@b37-ol-0-0-8393]--[@b41-ol-0-0-8393]).

In the colon, aberrant DNA methylation arises extremely early, initially in normal-appearing mucosa, and it may be part of the age-associated field defects observed in sporadic CRC ([@b42-ol-0-0-8393]). Hypermethylation in CpG islands has been demonstrated to be a novel mechanism of tumor suppressor gene silencing ([@b7-ol-0-0-8393],[@b8-ol-0-0-8393]). A number of genes have now been demonstrated to be hypermethylated in colorectal tumors, including *APC* ([@b11-ol-0-0-8393]), *MLH1* ([@b43-ol-0-0-8393]) and O^6^-methylguanine DNA methyltransferase ([@b44-ol-0-0-8393]). For example, the inactivation of the cyclin-dependent kinase inhibitor *P16*/*CDKN2A*/*INK4a* by methylation leads to the disruption of cell-cycle regulation and potentially provides a growth advantage to affected cells ([@b45-ol-0-0-8393]).

*PCDH*-γ-*A12* is a member of the protocadherin γ gene cluster, which includes 22 genes divided into 3 subfamilies (subfamily A, B and C) ([@b46-ol-0-0-8393]). The exon of *PCDH*-γ-*A12* encodes the extracellular region, which includes six cadherin ectodomains and a transmembrane region. These cadherin-like cell adhesion proteins most likely serve a critical role in the establishment and function of specific cell-cell connections in the brain and cancer ([@b18-ol-0-0-8393]). The hypermethylation of *PCDH*-γ-*A12* induces the downregulation of *PCDH*-γ-*A12* gene transcription by rendering the chromatin structure inaccessible to the transcription machinery in a variety of tumors including bladder cancer, breast cancer, acute lymphoblastic leukemia and non-small cell lung cancer ([@b17-ol-0-0-8393],[@b29-ol-0-0-8393],[@b47-ol-0-0-8393],[@b48-ol-0-0-8393]). The present study in CRC provides new evidence for the contribution of *PCDH*-γ-*A12* promoter hypermethylation to the occurrence and metastasis of CRC.

*SLC19A1* encodes a membrane protein that is a transporter of folate, and is involved in the regulation of intracellular concentrations of folate. SLC19A1 is also a major transporter of antifolate drugs used for certain types of cancer chemotherapy, including methotrexate (MTX) ([@b30-ol-0-0-8393]). The expression of SLC19A1 is downregulated following exposure to MTX in breast cancer, and a reverse correlation was identified between the promoter methylation and mRNA levels of SLC19A1. A variant of the *SLC19A1* gene is associated with metastatic colorectal cancer ([@b20-ol-0-0-8393]). The present study in CRC adds new evidence for the contribution of *SLC19A1* promoter hypermethylation to the occurrence and metastasis of CRC.

Certain studies have focused on the correlation between colorectal cancer clinical features and the methylation of certain genes, including *p15, APC* and *E-cadherin*, suggesting that the inactivation of certain tumor suppressor genes through aberrant promoter methylation of CpG islands may serve a role in the development of colorectal cancer ([@b49-ol-0-0-8393],[@b50-ol-0-0-8393]). Multiple methylation pathways may be involved in the tumorigenesis of CRC and associated with the aggressiveness of clinical disease ([@b37-ol-0-0-8393]). In the present study, the correlation between the methylation of *PCDH*-γ-*A12, SLC19A1*, *CREB* and *CYLD* and colorectal cancer clinical features was examined. However, no significant correlation was identified between *PCDH*-γ-*A12, SLC19A1*, *CREB* and *CYLD* methylation and the clinical features, which may be due to the lack of power in the samples used.

CEA is a member of a family of cell surface glycoproteins that are excessively produced in the majority of human colorectal carcinomas ([@b51-ol-0-0-8393]). CEA measurement is mainly used as a tumor marker to monitor colorectal carcinoma treatment, to identify recurrences following surgical resection and to localize cancer spread through measurement of biological fluids ([@b52-ol-0-0-8393],[@b53-ol-0-0-8393]). CA19-9 is a useful tumor-associated antigen for the serological detection of colorectal carcinomas, and may be used to monitor patients with advanced colorectal carcinomas ([@b54-ol-0-0-8393]). One aim of the present study was to observe whether the status of *PCDH*-γ-*A12, SLC19A1*, *CREB* and *CYLD* promoter methylation had a correlation with the serum level of CEA and CA19-9. However, no significant correlation was observed between *PCDH*-γ-*A12, SLC19A1*, *CREB* and *CYLD* promoter methylation and the serum level of CEA and CA19-9. This may imply that aberrant methylation of *PCDH*-γ-*A12, SLC19A1, CREB* and *CYLD* combined with conventional tumor markers could serve as complementary markers in the diagnosis of CRC. However, further study is necessary to confirm this hypothesis.

In conclusion, *PCDH*-γ-*A12* and *SLC19A1* promoters, but not *CREB* and *CYLD* promoters, are hypermethylated and contribute to the occurrence and metastasis of colorectal cancer. These findings may provide a new direction in the detection and treatment of CRC. Future research is required to determine the detailed mechanisms of how the *PCDH*-γ-*A12* and *SLC19A1* genes contribute to the risk of CRC.
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###### 

Clinical profiles of the colorectal cancer patients.

  Characteristics      Subgroup                     Patients, n
  -------------------- ---------------------------- -------------
  Gender               Male                         28
                       Female                       14
  Age (years)          ≤60                          16
                       \>60                         26
  TNM stage            1, 2                         21
                       3, 4                         21
  Lymph metastasis     Yes                          21
                       No                           21
  Distant metastasis   Yes                          8
                       No                           34
  CEA                  ≥5.0 ng/ml                   15
                       \<5.0 ng/ml                  27
  CA19-9               ≥37 U/ml                     9
                       \<37 U/ml                    33
  Tumor location       Colon                        26
                       Rectum                       16
  Differentiation      Poor                         10
                       Moderate                     32
                       Good                         0
  Tumor size           \<5 cm                       28
                       ≥5 cm                        14
  Histological         Adenocarcinoma               40
  classification       Mucinous adenocarcinoma      2
                       Undifferentiated carcinoma   0

TNM, tumor-node-metastasis; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9.

###### 

List of all primers used.

  Gene           Subgroup   Sense (5′-3′)            Antisense (5′-3′)      Size (bp)
  -------------- ---------- ------------------------ ---------------------- -----------
  *PCDH-γ-A12*   M          ATTAAGGTGGTGGCGGTGGAT    GACGCCGACGCTCCTATCAA   449
                 U          AAGGTGGTGGTGGTGGATAG     ACCAACACTCCTATCAAAC    443
  *SLC19A1*      M          TTGTTGTAGCGGTGTTGGAAGG   TCCGCCGCAACCTACGAAT    361
                 U          TTTGTTGTAGTGGTGTTGGAAG   TTCCACCACAACCTACAAAT   363
  *CREB*         M          CGGCGGTTAAGAGTAGAGTTA    GCGTCACTCACCAACACT     492
                 U          TGGTGGTTAAGAGTAGAGTTA    TCACTCACCAACACTCCAC    489
  *CYLD*         M          AGTTGGTGGTAGCGTAGCG      CATTCACTAACCTCGAACGA   495
                 U          TGGTGGTAGTGTAGTGTTT      TCACTAACCTCAAACAACA    489

*PCDH-γ-A12*, protocadherin γ subfamily A12; *SLC19A1*, solute carrier family 19 A 1; *CREB*, cAMP responsive element binding protein; *CYLD*, cylindromatosis; M, methylated; U, unmethylated.

###### 

Methylation status of *PCDH*-γ-*A12, SLC19A1, CREB* and *CYLD* genes in colorectal cancer and normal tissues.

  Gene             Group      Total   M    U    M%      χ^2^    P-value
  ---------------- ---------- ------- ---- ---- ------- ------- ---------
  *PCDH*-γ-*A12*   Cases      42      35   7    83.33   6.891   0.009
                   Controls   42      24   18   57.14           
  *SLC19A1*        Cases      42      33   9    78.57   9.894   0.002
                   Controls   42      19   23   45.24           
  *CREB*           Cases      42      11   31   26.19   2.779   0.095
                   Controls   42      5    37   11.90           
  *CYLD*           Cases      42      6    36   14.29   0.105   0.746
                   Controls   42      5    37   11.90           

*PCDH*-γ-*A12*, protocadherin γ subfamily A12; *SLC19A1*, solute carrier family 19 A 1; *CREB*, cAMP responsive element binding protein; *CYLD*, cylindromatosis; M, methylated; U, unmethylated.

###### 

Methylation status of *PCDH-γ-A12, SLC19A1, CREB* and *CYLD* genes in lymph metastasis and non-lymph metastasis colorectal cancer tissues.

  Gene         Subgroup   Total   M    U    M%       χ^2^    P-value
  ------------ ---------- ------- ---- ---- -------- ------- ---------
  PCDH-γ-A12   Cases      21      21   0    100.00   6.171   0.013
               Controls   21      14   7    66.67            
  SLC19A1      Cases      21      20   1    95.24    5.091   0.024
               Controls   21      13   8    61.90            
  CREB         Cases      21      7    14   33.33    1.109   0.292
               Controls   21      4    17   19.05            
  CYLD         Cases      21      4    17   19.05    0.194   0.659
               Controls   21      2    19   9.52             

*PCDH-γ-A12*, protocadherin γ subfamily A12; *SLC19A1*, solute carrier family 19 A 1; *CREB*, cAMP responsive element binding protein; *CYLD*, cylindromatosis; M, methylated; U, unmethylated.

###### 

Association between *PCDH-γ-A12, SLC19A1, CREB* and *CYLD* methylation in CRC serum and clinicopathological features.

                                                                  *PCDH*-γ-*A12*   *SLC19A1*   *CREB*   *CYLD*                                          
  ----------------------------- ---------------------------- ---- ---------------- ----------- -------- -------- --- ------- ---- ---- ------- --- ---- -------
  Gender                        Male                         28   25               3           0.306    21       7   0.690   7    21   1       4   24   1.000
                                Female                       14   10               4                    12       2           4    10           2   12   
  Age (years)                   ≤60                          16   14               2           0.887    10       6   0.109   4    12   1       3   13   0.846
                                \>60                         26   21               5                    23       3           7    19           3   23   
  TNM stage                     1, 2                         21   18               3           1.000    17       4   1.000   6    15   0.547   2   19   0.659
                                3, 4                         21   17               4                    16       5           5    16           4   17   
  Lymph metastasis              Yes                          21   21               0           0.013    20       1   0.024   7    14   0.292   4   17   0.756
                                No                           21   14               7                      13     8           4    17           2   19   
  Distant metastasis            Yes                          8    7                1           1.000    8        0   0.245   4    4    0.209   3   5    0.128
                                No                           34   28               6                    25       9           7    27           3   31   
  CEA                           ≥5.0 ng/ml                   15   12               3           1.000    10       5   0.313   3    12   0.754   3   12   0.742
                                \<5.0 ng/ml                  27   23               4                    23       4           8    19           3   24   
  CA19-9                        ≥37 U/ml                     9    7                2           1.000    6        3   0.600   3    6    0.903   2   7    0.818
                                \<37 U/ml                    33   28               5                    27       6           8    25           4   29   
  Tumor location                Colon                        26   21               5           0.887    23       3   0.109   8    18   0.618   3   23   0.846
                                Rectum                       16   14               2                    10       6           3    13           3   13   
  Differentiation               Poor                         10   9                1           0.871    9        1   0.570   4    6    0.468   2   8    0.941
                                Moderate                     32   26               6                    24       8           7    25           4   28   
                                Good                         0    0                0                    0        0           0    0            0   0    
  Tumor size                    \<5 cm                       28   23               5           1.000    22       6   1.000   7    21   1       3   25   0.640
                                ≥5 cm                        14   12               2                    11       3           4    10           3   11   
  Histological classification   Adenocarcinoma               40   33               7           1.000    31       9   1.000   10   30   1       4   36   0.558
                                Mucinous adenocarcinoma      2    2                0                    2        0           1    1            1   1    
                                Undifferentiated carcinoma   0    0                0                    0        0           0    0            0   0    

*PCDH-γ-A12*, protocadherin γ subfamily A12; *SLC19A1*, solute carrier family 19 A 1; *CREB*, cAMP responsive element binding protein; *CYLD*, cylindromatosis; M, methylated; U, unmethylated; TNM, tumor-node-metastasis; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9.
